165 related articles for article (PubMed ID: 38351437)
41. Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer.
Lin Y; Wang C; Gao W; Cui R; Liang J
Oncotarget; 2017 Jun; 8(26):42252-42261. PubMed ID: 28178685
[TBL] [Abstract][Full Text] [Related]
42. FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine-Refractory Differentiated Thyroid Cancer.
Nair A; Lemery SJ; Yang J; Marathe A; Zhao L; Zhao H; Jiang X; He K; Ladouceur G; Mitra AK; Zhou L; Fox E; Aungst S; Helms W; Keegan P; Pazdur R
Clin Cancer Res; 2015 Dec; 21(23):5205-8. PubMed ID: 26324740
[TBL] [Abstract][Full Text] [Related]
43. Comparative efficacy and safety of tyrosine kinase inhibitors for thyroid cancer: a systematic review and meta-analysis.
Oba T; Chino T; Soma A; Shimizu T; Ono M; Ito T; Kanai T; Maeno K; Ito KI
Endocr J; 2020 Dec; 67(12):1215-1226. PubMed ID: 32814730
[TBL] [Abstract][Full Text] [Related]
44. A proposed clinical scoring system for initiation of lenvatinib treatment in radioiodine-refractory thyroid cancer patients.
Fukuda N; Toda K; Udagawa S; Ohmoto A; Oki R; Suto H; Wang X; Hayashi N; Urasaki T; Sato Y; Nakano K; Ono M; Tomomatsu J; Mitani H; Takahashi S
Endocrine; 2022 Apr; 76(1):70-77. PubMed ID: 35088293
[TBL] [Abstract][Full Text] [Related]
45. Efficacy and safety of tyrosine kinase inhibitors for advanced metastatic thyroid cancer: A systematic review and network meta-analysis of randomized controlled trials.
Zhao M; Li R; Song Z; Miao C; Lu J
Medicine (Baltimore); 2024 Apr; 103(15):e37655. PubMed ID: 38608050
[TBL] [Abstract][Full Text] [Related]
46. Impact of baseline tumor burden on overall survival in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial.
Kiyota N; Tahara M; Robinson B; Schlumberger M; Sherman SI; Leboulleux S; Lee EK; Suzuki T; Ren M; Fushimi K; Wirth LJ
Cancer; 2022 Jun; 128(12):2281-2287. PubMed ID: 35380178
[TBL] [Abstract][Full Text] [Related]
47. Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives.
Costa R; Carneiro BA; Chandra S; Pai SG; Chae YK; Kaplan JB; Garrett HB; Agulnik M; Kopp PA; Giles FJ
Drug Des Devel Ther; 2016; 10():873-84. PubMed ID: 27013865
[TBL] [Abstract][Full Text] [Related]
48. Lenvatinib - A multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer.
Hewett Y; Ghimire S; Farooqi B; Shah BK
J Oncol Pharm Pract; 2018 Jan; 24(1):28-32. PubMed ID: 27856921
[TBL] [Abstract][Full Text] [Related]
49. [Lenvatinib in radioiodine refractory thyroid carcinomas].
de la Fouchardiere C
Bull Cancer; 2016 Nov; 103(11):905-910. PubMed ID: 27817859
[TBL] [Abstract][Full Text] [Related]
50. The experience of an Endocrinology Division on the use of tyrosine multikinase inhibitor therapy in patients with radioiodine-resistant differentiated thyroid cancer.
Jerkovich F; García Falcone MG; Pitoia F
Endocrine; 2019 Jun; 64(3):632-638. PubMed ID: 30820748
[TBL] [Abstract][Full Text] [Related]
51. Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid.
Tahara M; Schlumberger M; Elisei R; Habra MA; Kiyota N; Paschke R; Dutcus CE; Hihara T; McGrath S; Matijevic M; Kadowaki T; Funahashi Y; Sherman SI
Eur J Cancer; 2017 Apr; 75():213-221. PubMed ID: 28237867
[TBL] [Abstract][Full Text] [Related]
52. Real-world treatment patterns and clinical outcomes in patients with radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) treated with first line lenvatinib monotherapy in the United States.
Worden F; Rajkovic-Hooley O; Reynolds N; Milligan G; Zhang J
Endocrine; 2024 May; 84(2):663-669. PubMed ID: 38102498
[TBL] [Abstract][Full Text] [Related]
53. Lenvatinib and Subsequent Therapy for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Real-World Study of Clinical Effectiveness in the United States.
Kish JK; Chatterjee D; Wan Y; Yu HT; Liassou D; Feinberg BA
Adv Ther; 2020 Jun; 37(6):2841-2852. PubMed ID: 32382946
[TBL] [Abstract][Full Text] [Related]
54. Prolonged duration of response in lenvatinib responders with thyroid cancer.
Gianoukakis AG; Dutcus CE; Batty N; Guo M; Baig M
Endocr Relat Cancer; 2018 Jun; 25(6):699-704. PubMed ID: 29752332
[TBL] [Abstract][Full Text] [Related]
55. Use of multikinase inhibitors/lenvatinib concomitant with locoregional therapies for the treatment of radioiodine-refractory differentiated thyroid cancer.
Berciano-Guerrero MÁ
Cancer Med; 2022 Oct; 11 Suppl 1(Suppl 1):40-46. PubMed ID: 36202609
[TBL] [Abstract][Full Text] [Related]
56. Sorafenib and radioiodine-refractory differentiated thyroid cancer (RR-DTC): a systematic review and meta-analysis.
Feng G; Luo Y; Zhang Q; Zeng F; Xu J; Zhu J
Endocrine; 2020 Apr; 68(1):56-63. PubMed ID: 31955344
[TBL] [Abstract][Full Text] [Related]
57. Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial.
Brose MS; Robinson BG; Sherman SI; Jarzab B; Lin CC; Vaisman F; Hoff AO; Hitre E; Bowles DW; Sen S; Oliver JW; Banerjee K; Keam B; Capdevila J
Cancer; 2022 Dec; 128(24):4203-4212. PubMed ID: 36259380
[TBL] [Abstract][Full Text] [Related]
58. Lenvatinib complementary with radioiodine therapy for patients with advanced differentiated thyroid carcinoma: case reports and literature review.
Sheu NW; Jiang HJ; Wu CW; Chiang FY; Chiou HC; Hsiao PJ
World J Surg Oncol; 2019 May; 17(1):84. PubMed ID: 31103041
[TBL] [Abstract][Full Text] [Related]
59. Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer.
Capdevila J; Newbold K; Licitra L; Popovtzer A; Moreso F; Zamorano J; Kreissl M; Aller J; Grande E
Cancer Treat Rev; 2018 Sep; 69():164-176. PubMed ID: 30032061
[TBL] [Abstract][Full Text] [Related]
60. Antitumour effects of apatinib in progressive, metastatic differentiated thyroid cancer (DTC).
Shi L; You Q; Wang J; Wang H; Li S; Tian R; Yao X; Wu W; Zhang L; Wang F; Lin Y; Li S
Endocrine; 2022 Oct; 78(1):68-76. PubMed ID: 35767182
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
